Barclays’s Colgate-Palmolive CL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-100
| Closed | -$7.99K | – | 5299 |
|
|
2025
Q3 | $7.99K | Buy |
+100
| New | +$8.53K | ﹤0.01% | 5038 |
|
|
2023
Q4 | – | Sell |
-80,000
| Closed | -$5.69M | – | 5235 |
|
|
2023
Q3 | $5.69M | Buy |
+80,000
| New | +$5.98M | ﹤0.01% | 1253 |
|
|
2023
Q1 | – | Sell |
-4,400
| Closed | -$347K | – | 5122 |
|
|
2022
Q4 | $347K | Buy |
+4,400
| New | +$330K | ﹤0.01% | 3532 |
|
|
2021
Q1 | – | Sell |
-1,100
| Closed | -$94K | – | 4743 |
|
|
2020
Q4 | $94K | Hold |
1,100
| – | – | ﹤0.01% | 4154 |
|
|
2020
Q3 | $85K | Sell |
1,100
-29,600
| -96% | -$2.26M | ﹤0.01% | 4329 |
|
|
2020
Q2 | $2.25M | Sell |
30,700
-230,700
| -88% | -$16.4M | ﹤0.01% | 2013 |
|
|
2020
Q1 | $17.3M | Buy |
261,400
+206,900
| +380% | +$14.6M | 0.01% | 701 |
|
|
2019
Q4 | $3.75M | Sell |
54,500
-145,400
| -73% | -$9.91M | ﹤0.01% | 2322 |
|
|
2019
Q3 | $14.7M | Buy |
199,900
+119,000
| +147% | +$8.63M | 0.01% | 1060 |
|
|
2019
Q2 | $5.8M | Sell |
80,900
-125,400
| -61% | -$8.9M | ﹤0.01% | 1735 |
|
|
2019
Q1 | $14.1M | Sell |
206,300
-189,100
| -48% | -$12.2M | 0.01% | 1025 |
|
|
2018
Q4 | $23.5M | Buy |
395,400
+308,800
| +357% | +$19.3M | 0.02% | 677 |
|
|
2018
Q3 | $5.8M | Sell |
86,600
-63,500
| -42% | -$4.23M | ﹤0.01% | 1665 |
|
|
2018
Q2 | $9.73M | Buy |
150,100
+39,400
| +36% | +$2.58M | 0.01% | 1244 |
|
|
2018
Q1 | $7.93M | Buy |
110,700
+74,100
| +202% | +$5.33M | 0.01% | 1317 |
|
|
2017
Q4 | $2.76M | Sell |
36,600
-19,800
| -35% | -$1.45M | ﹤0.01% | 2142 |
|
|
2017
Q3 | $4.11M | Sell |
56,400
-7,600
| -12% | -$548K | ﹤0.01% | 1689 |
|
|
2017
Q2 | $4.74M | Buy |
64,000
+34,500
| +117% | +$2.56M | 0.01% | 1511 |
|
|
2017
Q1 | $2.16M | Sell |
29,500
-22,400
| -43% | -$1.57M | ﹤0.01% | 2022 |
|
|
2016
Q4 | $3.4M | Sell |
51,900
-5,700
| -10% | -$391K | ﹤0.01% | 1675 |
|
|
2016
Q3 | $4.27M | Buy |
57,600
+20,100
| +54% | +$1.49M | ﹤0.01% | 1413 |
|
|
2016
Q2 | $2.75M | Buy |
37,500
+4,500
| +14% | +$320K | ﹤0.01% | 1756 |
|
|
2016
Q1 | $2.31M | Sell |
33,000
-179,800
| -84% | -$12M | ﹤0.01% | 1789 |
|
|
2015
Q4 | $14M | Sell |
212,800
-12,500
| -6% | -$832K | 0.02% | 724 |
|
|
2015
Q3 | $14.2M | Sell |
225,300
-37,500
| -14% | -$2.45M | 0.02% | 757 |
|
|
2015
Q2 | $17.1M | Sell |
262,800
-7,900
| -3% | -$536K | 0.02% | 732 |
|
|
2015
Q1 | $18.7M | Sell |
270,700
-69,100
| -20% | -$4.78M | 0.02% | 715 |
|
|
2014
Q4 | $23.4M | Buy |
339,800
+84,900
| +33% | +$5.73M | 0.02% | 677 |
|
|
2014
Q3 | $16.6M | Sell |
254,900
-11,200
| -4% | -$739K | 0.02% | 836 |
|
|
2014
Q2 | $18.1M | Sell |
266,100
-13,200
| -5% | -$885K | 0.02% | 759 |
|
|
2014
Q1 | $17.9M | Sell |
279,300
-182,800
| -40% | -$11.5M | 0.02% | 763 |
|
|
2013
Q4 | $30M | Buy |
462,100
+94,900
| +26% | +$6.07M | 0.03% | 547 |
|
|
2013
Q3 | $21.7M | Sell |
367,200
-26,500
| -7% | -$1.57M | 0.03% | 627 |
|
|
2013
Q2 | $22.6M | Buy |
+393,700
| New | +$23.4M | 0.03% | 591 |
|
Other funds holding CL
VCM
DAM
VPM
Barclays's CL Position: Q1 2026 in Review
Barclays reduced its Colgate-Palmolive (CL) stake by 22% in Q1 2026, selling an estimated $51.9M and leaving 2,113,254 shares worth $180M. The position accounts for 0.04% of the portfolio, ranked #322.
Barclays first reported a position in CL in Q2 2013 and has held it in 52 quarters since. The position peaked at $794M in Q3 2024. 1,948 funds tracked by Wall St. Rank hold CL as of Q1 2026.
- Barclays held 2,113,254 shares of Colgate-Palmolive worth $180M as of Q1 2026.
- Barclays sold 581,983 Colgate-Palmolive shares in Q1 2026, an estimated $51.9M.
- Colgate-Palmolive made up 0.04% of Barclays's portfolio in Q1 2026, its #322 holding.
- Barclays first reported a position in Colgate-Palmolive in Q2 2013 and has held it in 52 quarters since.
- Barclays's Colgate-Palmolive position peaked at $794M in Q3 2024.
- 1,948 funds tracked by Wall St. Rank held Colgate-Palmolive as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.